glioblastoma

(redirected from glioblastoma multiforme)
Also found in: Thesaurus, Medical, Acronyms, Wikipedia.

gli·o·blas·to·ma

 (glē′ō-blă-stō′mə, glī′-)
n. pl. gli·o·blas·to·mas or gli·o·blas·to·ma·ta (-mə-tə)
A malignant tumor of the central nervous system, usually occurring in the cerebrum of adults.

glioblastoma

(ˌɡlaɪəʊblæsˈtəʊmə; ˌɡliːəʊ-)
adj
(Pathology) med a malignant tumour of the central nervous system
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.glioblastoma - a fast-growing malignant brain tumor composed of spongioblasts; nearly always fatal
brain tumor, brain tumour - a tumor in the brain
Translations
glioblastoma

glioblastoma

n. glioblastoma, tipo de tumor cerebral.

glioblastoma

n glioblastoma m; glioblastoma multiforme glioblastoma multiforme
References in periodicals archive ?
Keywords: Glioblastoma multiforme (GBM), Radiosensitizer, Gemcitabine.
Australian oncology company Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) stated on Friday that it has filed its Orphan Drug Designation (ODD) with the US Food and Drug Administration (FDA) for its investigational new drug, GDC-0084, for the treatment of glioblastoma multiforme.
This study is an adaptive (trial design can be changed once it starts), randomized controlled, Phase III clinical trial in adult patients with diagnoses of glioblastoma multiforme or gliosarcoma confirmed histologically (through microscopic examination of tumor cells) at initial diagnosis, who have been previously treated with surgery (if appropriate), standard of care chemo-radiation with temozolomide, with or without adjuvant temozolomide, and bevacizumab.
Patients diagnosed with glioblastoma multiforme are expected to live about 15 months after diagnosis.
Visit the Glioblastoma Multiforme Drugs Market 2013-2020 report https://www.
This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
The study remains open to patients whose glioblastoma multiforme has returned following surgical removal.
Perhaps the most frightening malignancy one can be diagnosed with is a form of brain cancer called glioblastoma multiforme.
The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).
PCT manufactures ICT-121, a dendritic cell vaccine targeting CD 133 cells, in a phase 1 clinical trial for recurrent glioblastoma multiforme (GBM) pursuant to a services agreement between the companies.